Bestim

• CAT Number: I023292
• CAS Number: 66471-20-3
• Molecular Formula: C16H19N3O5
• Molecular Weight: 333.34
• Purity: 98%
• Synonyms: Bestim
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N5-((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)-L-glutamine
• InChI: InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13-/m0/s1
• InChIKey: CATMPQFFVNKDEY-AAEUAGOBSA-N
• SMILES: O=C(O)[C@H](CC1=CNC2=C1C=CC=C2)NC(CC[C@@H](C(O)=O)N)=O

Bestim(CAT: I023292) is a synthetic immunomodulatory peptide that enhances immune responses by stimulating T-cell and macrophage activity. It is known to promote the production of cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ), which are crucial for adaptive and innate immune functions. Bestim has been extensively studied for its potential in improving immune responses in infectious diseases, cancer immunotherapy, and vaccine adjuvant development. Its ability to modulate immune pathways makes it a valuable tool in immunological research and therapeutic applications targeting immune dysfunction and immunosuppression.

Reference

1: Kolobov AA, Kolodkin NI, Zolotarev IuA, Tathill C, Navolotskaia EV. [Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes]. Bioorg Khim. 2008 Jan-Feb;34(1):43-9. Russian. PubMed PMID: 18365736.
2: Zabolotnykh NV, Vinogradova TI, Vasil’eva SN. [Activating effect of bestim on the macrophages in experimental tuberculosis of varying severity]. Probl Tuberk Bolezn Legk. 2003;(10):53-6. Russian. PubMed PMID: 14669634.
3: Tkacheva AG, Kalev OF, Dolgushina AI, Antipina TV. [Impact of Bestim on the immunological status and clinical course of ulcer]. Eksp Klin Gastroenterol. 2004;(6):29-33, 163. Russian. PubMed PMID: 16259438.
4: Rudenko MY. [IMMUNE SYSTEM DATA IN PATIENTS WITH PERSISTENT RECURENT HERPES VIRUS INFECTIONS IN DYNAMICS OF COMPLEX THERAPY]. Lik Sprava. 2015 Jul-Sep;(5-6):14-20. Russian. PubMed PMID: 27089710.
5: Vinogradova TI, Vitovskaia ML, Zabolotnykh NV, Kovalenko AL, Ariél’ BM, Shchegoleva RA. [The influence of immunotropic drugs on reparative processes in the lungs experimental chemotherapy drug resistant tuberculosis]. Eksp Klin Farmakol. 2014;77(7):11-5. Russian. PubMed PMID: 25322647.
6: Yakimets AV, Zozulya SA, Oleichik IV, Klyushnik TP. [Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):70-76. doi: 10.17116/jnevro20181183170-76. Russian. PubMed PMID: 29652309.